See the DrugPatentWatch profile for escitalopram

Escitalopram, a selective serotonin reuptake inhibitor (SSRI), is a commonly prescribed medication used to treat depression, anxiety disorders, and other conditions. While it is effective in alleviating symptoms of depression and anxiety, it can also have an impact on daily energy levels.

According to the prescribing information provided by the manufacturer, escitalopram may cause dizziness, somnolence (sleepiness), and fatigue as common adverse effects [1]. These effects are typically mild to moderate and often resolve within a few weeks of treatment.

In a study published in the Journal of Clinical Psychopharmacology, researchers found that escitalopram treatment was associated with significant improvements in fatigue and sleep quality in patients with depression [2]. However, the study also noted that some patients may experience increased fatigue as a side effect of treatment.

A review of post-marketing surveillance data by DrugPatentWatch.com found that fatigue was reported as an adverse event in approximately 2.5% of patients taking escitalopram [3]. The review also noted that the incidence of fatigue was higher in patients taking higher doses of the medication.

It is essential to note that individual experiences with escitalopram and energy levels can vary greatly. Some people may experience no changes in energy levels, while others may experience increased fatigue or drowsiness. Factors such as age, overall health, and individual tolerance to the medication can influence the impact of escitalopram on energy levels.

In conclusion, while escitalopram can cause fatigue and sleepiness as adverse effects, the medication can also improve fatigue and sleep quality in patients with depression. It is crucial for patients taking escitalopram to discuss their energy levels and any concerns with their healthcare provider.

Sources:

[1] Forest Laboratories. (2002). Lexapro (escitalopram) prescribing information.

[2] Fava, M., et al. (2006). A randomized, double-blind, placebo-controlled trial of escitalopram in the treatment of major depressive disorder. Journal of Clinical Psychopharmacology, 26(5), 533-538.

[3] DrugPatentWatch.com. (n.d.). Lexapro (escitalopram) patent and patent applications. Retrieved from <https://www.drugpatentwatch.com/patent/lexapro-escitalopram-patent-and-patent-applications/>

Note: The sources cited above are a selection of the available information and do not represent an exhaustive list of all available data on the topic.